Manufacturers report positive results from the JUPITER-02 Phase III study for toripalimab in recurrent or metastatic nasopharyngeal carcinoma

In interim analysis of the JUPITER-02 STUDY (n=289), this PD-1 monoclonal antibody as used as a first-line treatmen .improved progression free survival rate vs placebo when added to standard therapy (gemcitabine and cisplatin)

Source:

Biospace Inc.